Patrick Coulombier (Chief Executive Officer)
|PATRICK COULOMBIER, former chief operating officer of CARMAT, has headed the project team for the CARMAT bioprosthetic artificial heart within the Airbus Group since July 2001. Before that he worked for MBDA France as director of two international programs in the area of defense, one concerning a British air combat training system and the other relating to a Franco-German drone system. Between 1978 and 1990, before joining MBDA France, Patrick Coulombier had a number of diff erent research and development posts in connection with a range of aeronautic and space projects at Thales Avionique (Airbus A130, A320, Rafale Combat Aircraft, Super Puma Helicopter and the Hermes Spacecraft). Patrick Coulombier has a degree in electronic engineering.|
Christophe Aubert (Chief Technical Officer)
Christophe Aubert graduated from the University of Applied Sciences of Neuchâtel, Switzerland, with a diploma in Micro Technologies, in 1988. He started his career in the Watch making industry at Swatch, in the design team of Jacques Mueller, inventor of the Swatch watch. There he designed and patented, developed and registered the first ever single use patch pump, some 20 years ago. He subsequently studied Biomaterial and Artificial Organs at the Swiss Institute of Technology of Lausanne (EPFL) as a postgrad training. Attracted by the Medical field, he moved to the Medical Devices industry from 1992 to 1997 during which time he had the chance to design and develop implantable devices such as pumps and anti-siphoning devices. He realized that significant cultural and technical gaps existed between the Pharma Industry, his customers, and the Medical Devices Industry, gaps that made communication sometimes difficult. In an attempt to bridge these gaps and to deepen his knowledge of the Pharma Industry, he decided to join Ipsen, a French pharmaceutical company involved in biotechnology, where he continued to design and develop innovative Drug storage and delivery solutions in very close collaboration with Formulation team. This collaboration resulted in unique and commercially successful Drug-Device combination products the Group mostly relies on to ensure its growth for the next decade. He left Ipsen in 2008 to set-up his own business providing R&D, Design Control, trouble-shooting and communication bridging services to Medical Devices and Pharmaceutical companies, ranging from start-up biotech to Big Pharma and well known Medical Devices manufacturers.